CMS vs ORGO: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. CMS and ORGO share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined CMS and ORGO exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

CMS Energy Corporation is a holding company headquartered in Jackson, Michigan, whose principal business is Consumers Energy, one of the largest regulated combination utilities in the country, delivering electricity and natural gas to roughly 6.7 million of Michigan's 10 million residents. The company also runs a smaller non-utility enterprise segment (NorthStar Clean Energy) involved in independent power and renewable projects. Because the vast majority of earnings come from rate-regulated operations, CMS Energy's profit is driven largely by the rate base it invests in and the returns approved by the Michigan Public Service Commission.

Full CMS guide

Organogenesis Holdings Inc. is a regenerative medicine company that develops, manufactures, and commercializes products for the advanced wound care and surgical and sports medicine markets. Its advanced wound care line includes bioengineered and tissue-based products such as Apligraf, a bi-layered skin substitute for venous leg ulcers and diabetic foot ulcers; PuraPly and PuraPly AM, an antimicrobial wound matrix; and Affinity, a fresh human placental allograft. Its surgical and sports medicine products include ReNu, a cryopreserved amniotic suspension allograft, and NuCel. The company became publicly traded in 2018 through a SPAC merger with Avista Healthcare Public Acquisition Corp. and trades on the Nasdaq under the ticker ORGO. Because a large portion of its wound care revenue is billed to Medicare, the business is unusually sensitive to how the Centers for Medicare and Medicaid Services chooses to pay for skin substitutes.

Full ORGO guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• CMS drivers: Rate-base and capital plan growth; Clean energy transformation.
• ORGO drivers: CMS reimbursement reset and market adaptation; ReNu BLA in knee osteoarthritis.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: As a capital-intensive regulated utility, CMS Energy carries substantial debt and is sensitive to interest rates, which raise financing costs and can weigh on the share price and valuation. For ORGO, the dominant risk is Medicare reimbursement policy: a large share of revenue depends on how CMS pays for skin substitutes, and the CY 2026 payment reform already drove a sharp advanced wound care revenue decline and a large cut to full-year guidance versus 2025.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick CMS if you believe its drivers more; ORGO if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the CMS and ORGO guides.

CMS. CMS Energy trades at a premium utility multiple in the low-20s times earnings, reflecting its consistent regulated growth and long dividend record. In Q1 2026 the company reported operating revenue of about $2.73 billion and adjusted EPS of $1.13, beating estimates, and reaffirmed full-year guidance. Valuation and yield tend to move with interest rates, so the stock often behaves more like a bond-proxy than a cyclical name.

ORGO. Figures here are qualitative and tied to the asOf date; verify live numbers in the latest filings before acting. Because 2026 is a reimbursement-driven transition year with sharply lower guidance, trailing and forward earnings multiples are unreliable, and the stock's value hinges more on whether the wound care market normalizes and whether ReNu is approved than on any single quarter's results. Do not treat any of this as a price target or a recommendation.

Headline figures (approximate, July 2026): CMS shows market cap ~$24 billion, revenue (ttm) ~$8 billion, 2026 adjusted eps guidance ~$3.83 to $3.90, p/e ratio (trailing) ~21x; ORGO shows revenue trajectory Guided full-year 2026 net revenue sharply below record 2025, reflecting a projected double-digit percentage decline driven by CMS reimbursement and coverage changes, advanced wound care Reported a steep year-over-year decline in early 2026, the segment most exposed to the skin-substitute payment reform, profitability Under pressure during the 2026 transition as revenue contracts faster than the cost base; management frames 2026 as a reset year with recovery targeted for 2027, market cap Small-cap; the stock traded at only a few dollars per share in mid-2026, so market value is modest relative to its former highs.

CMS and ORGO are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined CMS and ORGO exposure against your real portfolio. It is not an investment adviser.